ImmunityBio's stock took a hit as the FDA flagged its cancer drug promotion as misleading. Investors bailed, but what does this mean for the biotech's future?
Jun 13, 2026
Jun 13, 2026
Jun 13, 2026
Jun 13, 2026
Jun 13, 2026
Jun 13, 2026
Jun 13, 2026
Jun 13, 2026